 This study has demonstrated the potential of a new type of nanoparticle-based vaccine for enhancing the immunogenicity of cancer vaccines. This novel vaccine, which combines a dendrimor polypeptide nanoparticle with an OVA slash neoantigen-based vaccine, was found to be more effective than other commonly used adjuvants at stimulating anti-tumor immunity. Additionally, when combined with an anti-PD-1 antibody, it was also shown to be effective at preventing tumor recurrence in a postoperative recurrent tumor model. These results suggest that this type of vaccine could be a promising approach for treating cancer patients. This article was authored by Rui Zhang, Lin Tang, Yuxi Wang, and others.